Goldman Sachs Group Inc vs Tempus AI — how do they compare? Goldman Sachs Group Inc trades at $889.8 (market cap $256.98B), while Tempus AI trades at $70.06 (market cap $12.58B). The key difference: Goldman Sachs Group Inc is far larger — about 20.4× Tempus AI's market cap, and Goldman Sachs Group Inc pays a 2.27% dividend while Tempus AI pays none. Which is the better fit depends on your goals — on Pluang, investors hold Goldman Sachs Group Inc for 101 Days and Tempus AI for 22 Days on average.
| GS | TEM | |
|---|---|---|
Market Cap | $256.98B | $12.58B |
Volume | 1,748,426 | 7,444,569 |
Sector | Financials | Broad Market / Factor |
52-Week High | $1.15K | $99.28 |
52-Week Low | $744.60 | $41.55 |
Typical Hold Time | 101 Days | 22 Days |
Enterprise Value | $814.98B | $13.21B |
Dividend Yield | 2.27% | — |
Signals from Pluang's Aura AI — not financial advice
Goldman Sachs (GS) trades at $887.21, down 1.11% on the day, with a bearish technical signal despite strong fundamental performance. The company has delivered three consecutive quarterly earnings beats, with Q2 2026 EPS of $20.98 significantly exceeding expectations of $14.47. Revenue growth accelerated to $58.28 billion in 2025, while net income margin improved to 29.46%. Analyst consensus remains positive with a $1,130 price target, though technical indicators show selling pressure.
GS presents a compelling value opportunity with a P/E of 13.63 below industry averages, supported by robust earnings growth and a 31.68% net income margin. However, negative operating cash flow of -$45.15 billion in 2025 and bearish technical momentum create near-term headwinds. The stock's 18.33% ROE and dividend yield of approximately 0.56% provide shareholder returns, but investors should monitor cash flow trends and FICC business performance highlighted in recent management commentary.
Tempus AI (TEM) trades at $72.15, up 2.65% today, with a bullish technical signal and strong analyst support. The stock shows recent earnings beats but remains unprofitable, with a net income margin of -17.77% for 2026. Positive developments include FDA clearance for an AI product and expanded data partnerships, fueling investor optimism in the healthtech sector.
Outlook is cautiously optimistic given growth potential in AI-driven diagnostics, but high valuation (P/S 8.61) and persistent losses pose risks. Upside hinges on revenue scaling and path to profitability, with a consensus price target of $72.60 suggesting limited near-term gains from current levels.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
The Goldman Sachs Group, Inc., a bank holding company, is a global investment banking and securities firm specializing in investment banking, trading and principal investments, asset management and securities services. The Company provides services to corporations, financial institutions, governments, and high-net worth individuals.
Read more on GS →Tempus AI Inc is a technology company. It has built the Tempus Platform, which comprises both a technology platform to free healthcare data from silos and an operating system to make the resulting data useful. Its Intelligent Diagnostics use AI, including generative AI, to make laboratory tests more accurate, tailored, and personal.
Read more on TEM →